- Home
- ANAB vs GOOD Comparison
ANAB vs GOOD Comparison
Compare ANAB & GOOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- GOOD
- Stock Information
- Founded
- ANAB 2005
- GOOD 2003
- Country
- ANAB United States
- GOOD United States
- Employees
- ANAB N/A
- GOOD N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- GOOD Real Estate Investment Trusts
- Sector
- ANAB Health Care
- GOOD Real Estate
- Exchange
- ANAB Nasdaq
- GOOD Nasdaq
- Market Cap
- ANAB 659.6M
- GOOD 578.7M
- IPO Year
- ANAB 2017
- GOOD N/A
- Fundamental
- Price
- ANAB $31.83
- GOOD $11.46
- Analyst Decision
- ANAB Buy
- GOOD Hold
- Analyst Count
- ANAB 10
- GOOD 1
- Target Price
- ANAB $50.63
- GOOD $15.00
- AVG Volume (30 Days)
- ANAB 749.6K
- GOOD 484.1K
- Earning Date
- ANAB 11-04-2025
- GOOD 11-03-2025
- Dividend Yield
- ANAB N/A
- GOOD 10.45%
- EPS Growth
- ANAB N/A
- GOOD N/A
- EPS
- ANAB N/A
- GOOD 0.36
- Revenue
- ANAB $123,164,000.00
- GOOD $153,643,000.00
- Revenue This Year
- ANAB $11.40
- GOOD $7.51
- Revenue Next Year
- ANAB $8.17
- GOOD $4.39
- P/E Ratio
- ANAB N/A
- GOOD $32.24
- Revenue Growth
- ANAB 304.17
- GOOD 5.85
- 52 Week Low
- ANAB $12.21
- GOOD $11.31
- 52 Week High
- ANAB $36.54
- GOOD $17.88
- Technical
- Relative Strength Index (RSI)
- ANAB 71.43
- GOOD 17.64
- Support Level
- ANAB $29.49
- GOOD $12.18
- Resistance Level
- ANAB $32.24
- GOOD $12.31
- Average True Range (ATR)
- ANAB 2.08
- GOOD 0.21
- MACD
- ANAB 0.81
- GOOD -0.11
- Stochastic Oscillator
- ANAB 82.04
- GOOD 1.05
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.